PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Aclaris Therapeutics Inc | ACRS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.065 | -3.65% | 1.715 | 1.78 | 1.69 | 1.77 | 1.78 | 11:44:25 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 1.71 | 1.72 | 0.01 | 0.58% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 438 | 101,180 | $ 1.73 | $ 174,797 | 1,540,520 | 0.74 - 9.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:44:26 | 100 | $ 1.715 | USD |
Aclaris Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 71.98M | 41.37M | $ -132.74M | -4.04 | - | 39.59M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Aclaris Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/12/2019 | 16:01 | GlobeNewswire Inc. | Aclaris Therapeutics to Present at Upcoming Investor.. |
| 11/07/2019 | 17:03 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/07/2019 | 16:18 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/07/2019 | 16:01 | GlobeNewswire Inc. | Aclaris Therapeutics Reports Third Quarter 2019 Financial.. |
| 10/31/2019 | 17:27 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) |
| 10/31/2019 | 16:18 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/31/2019 | 16:01 | GlobeNewswire Inc. | Aclaris Therapeutics to Announce Third Quarter 2019.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACRS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.65 | 1.95 | 1.47 | 1.87 | 660,167 | 0.065 | 3.94% |
| 1 Month | 1.57 | 2.05 | 1.39 | 1.75 | 1,252,974 | 0.145 | 9.24% |
| 3 Months | 0.9686 | 2.32 | 0.8585 | 1.53 | 1,860,188 | 0.7464 | 77.06% |
| 6 Months | 5.70 | 5.95 | 0.74 | 1.76 | 1,360,925 | -3.99 | -69.91% |
| 1 Year | 9.70 | 9.85 | 0.74 | 3.15 | 970,015 | -7.99 | -82.32% |
| 3 Years | 23.12 | 33.25 | 0.74 | 10.49 | 519,280 | -21.41 | -92.58% |
| 5 Years | 11.94 | 33.88 | 0.74 | 10.92 | 397,067 | -10.23 | -85.64% |
Aclaris Therapeutics Description
| Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which operates in United States. It focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company holds a drug candidate, A-101 Topical Solution which is a proprietary high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis (SK) a common non-malignant skin tumor. Its pipeline of drug candidates includes A-101 as a Topical Solution for treatment of SK, common warts; A-102 as a gel dosage form for treatment of SK and warts and A-201 and A-301 as an oral and topical formulation for treatment of autoimmune dermatologic respectively. |
